Partners with independent primary care physician groups to manage Medicare Advantage patients under value-based, full-risk contracts.
Partners with independent primary care physician groups to manage Medicare Advantage patients under value-based, full-risk contracts.
Receives a fixed share of each Medicare Advantage member's premium from the health plan and pays the medical bills, so it profits when members' care costs less than the premium and loses when costs run higher; the physician groups share in the result. It has pulled back from some unprofitable markets.
Moat: narrow (switching costs, data, process know-how). Long-term partnerships with physician groups embed agilon's risk-management platform and analytics into daily care.
Headquarters: Long Beach, California · Founded: 2016 · Employees: 856
Size agilon health (AGL) is a United States Health Care company (Medical/Nursing Services) with a market value of $1.52B, the 1966th largest of 3,085 United States companies the cockpit tracks. Shares closed at $90.53 on 18 Nov 2026.
Performance Over six months the shares gained 11.8%, against +17.1% for the median peer and -2.2% for the United States market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue grew 2.0% over the last twelve months (peer median +9.2%); the operating margin is -1.7% (peer median 6.2%).
Valuation It trades at 34.1× forward earnings against a peer median of 29.4× (6th most expensive of 16).
Short interest Short interest is 5.0% of the free float (30 Oct 2026).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $6.00B | $5.93B | $6.06B | $4.32B | $2.39B |
| Revenue growth | — | -2% | +40% | +81% | — |
| Gross profit | $152M | -$189M | -$19.6M | $53.6M | $102M |
| EBITDA | -$72.2M | -$392M | -$259M | -$212M | -$89.1M |
| Net income | -$106M | -$405M | -$251M | -$215M | -$107M |
| Free cash flow | -$18.6M | -$119M | -$71.0M | -$172M | -$146M |
| Capital expenditure | $20.4M | $43.1M | $41.3M | $30.8M | $32.7M |
| Total debt | $33.4M | $36.8M | $44.0M | $52.3M | $56.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| agilon health AGL | $1.52B | +12% | +2% | -2% | 34.1× | n/a |
| CVS Health CVS | $104B | -13% | +7% | 4% | 9.6× | -3.8% |
| Privia Health PRVA | $3.14B | +6% | +19% | 2% | 55.1× | n/a |
| Clover Health Investments CLOV | $2.21B | +16% | +54% | 0% | 52.0× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AGL | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.3% | +1.3% | 10th lowest of 21 |
| 6-month return | +11.8% | +17.1% | 10th lowest of 21 |
| Distance from 52-week high | -31.9% | -22.2% | 6th lowest of 21 |
| Revenue growth (TTM) | +2.0% | +9.2% | 8th lowest of 21 |
| Operating margin | -1.7% | 6.2% | 6th lowest of 21 |
| Forward P/E | 34.1× | 29.4× | 6th most expensive of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| agilon health AGL | United States | $1.52B | +12% | +2% | -2% | 34.1× | n/a | n/a |
| GeneDx WGS | United States | $1.56B | +16% | +15% | -14% | 54.2× | n/a | n/a |
| Teladoc Health TDOC | United States | $1.47B | +24% | -2% | -5% | n/a | -6.4% | +18.3% |
| Ambea AMBEA.ST | Sweden | $1.59B | +28% | +11% | 9% | 15.2× | 1.1% | +7.7% |
| Sonida Senior Living SNDA | United States | $1.59B | -11% | +70% | -8% | n/a | n/a | n/a |
| H.U.Group 4544.T | Japan | $1.44B | +24% | +1% | 3% | 39.9× | 9.7% | +2.1% |
| U.S. Physical Therapy USPH | United States | $1.42B | +53% | +10% | 10% | 29.4× | 18.8% | +13.0% |
| Personalis PSNL | United States | $1.62B | +88% | +17% | -157% | n/a | n/a | n/a |
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.69B | +18% | +24% | 32% | 63.0× | 40.4% | +16.7% |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.36B | -47% | +8% | 3% | 33.5× | 3.5% | -5.1% |
| Dian Diagnostics 300244.SZ | China | $1.70B | +1% | -5% | 9% | 21.8× | 0.3% | -1.1% |
| Lumexa Imaging LMRI | United States | $1.35B | +89% | +8% | 2% | 16.0× | n/a | n/a |
| Clariane CLARI.PA | France | $1.32B | -20% | +1% | 6% | 8.2× | 6.8% | +6.5% |
| Emeis EMEIS.PA | France | $1.78B | -33% | +4% | 3% | n/a | 21.2% | +8.5% |
| Diagnostyka DIA.WA | Poland | $1.28B | -6% | +19% | 15% | 19.5× | 7.3% | +18.9% |
| Pennant PNTG | United States | $1.26B | +1% | +39% | 6% | 23.7× | 20.7% | +19.4% |
| OPKO Health OPK | United States | $1.25B | +37% | -22% | -29% | n/a | n/a | n/a |
| Metropolis Healthcare METROPOLIS.NS | India | $1.25B | +11% | +20% | 18% | 44.5× | 32.4% | +10.5% |
| Guangzhou Kingmed Diagnostics 603882.SS | China | $1.86B | +5% | -3% | 7% | 29.9× | 5.4% | -6.1% |
| Dr. Agarwal's Health Care AGARWALEYE.NS | India | $1.86B | +20% | +26% | 15% | 77.1× | 43.0% | +26.9% |
| Nutex Health NUTX | United States | $1.19B | +42% | -19% | 39% | 6.5× | -18.0% | +253.5% |